This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
June 25, 2019
MIPS ACQUIRES THE BRAND GLIDEWEAR AND THE ASSOCIATED PATENT RIGHTS
June 24, 2019
Karo Pharma acquires Trimb for MSEK 3,400
June 19, 2019
GenSight Biologics expands its Board of Directors with the appointments of Maritza McIntyre and Sofinnova Partners
June 16, 2019
New Data Presented from Oncopeptides’ Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress
June 14, 2019
New Data Presented at 24th EHA Congress from Oncopeptides’ Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)
June 13, 2019
Oncopeptides will host a Webcast on Monday, 17 June at 09:00 (CET) to review and update presentations from European Hematology (EHA) meeting
June 12, 2019
Strongbridge Biopharma plc to Present at the 2019 JMP Securities Life Sciences Conference
June 12, 2019
Altimmune Appoints Will Brown as Chief Financial Officer
June 10, 2019
Altimmune Announces Successful Pre-IND Meeting with FDA
June 05, 2019
Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs